Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Gafvex - Philippines FDA Drug Approval Details

Approvals/Philippines FDA/Gafvex

Approved

STANDARD

Gafvex

Admac Lifesciences🇵🇭 Food and Drug Administration - Philippines

Approval Date: Jul 14, 2025
Approval ID: 6015961252d4e830
Company: Admac Lifesciences
Type: Standard

Approval Details

Approval Id: 6015961252d4e830
Drug Approval Philippines Name: Gafvex
Product Name: Gafvex
Registration Number: DR-XY44664
Brand Name: Gafvex
Generic Name: Gefitinib
Dosage Form: Film-Coated Tablet
Dosage Strength: 250mg
Manufacturer: Admac Lifesciences
Importer: VE Pharma, Inc.
Distributor: VE Pharma, Inc.
Issuance Date: 24 January 2025
Expiry Date: 22 June 2030
Pharmacologic Category: Antineoplastic (Protein Kinase Inhibitor)
Classification: Prescription Drug (RX)

Active Ingredients

Approved

Quick Info

Agency

Philippines FDA

Country

🇵🇭

Approval Date

Jul 14, 2025

Approval ID

6015961252d4e830

Type

Standard

Back to Philippines FDA Approvals